Publications: Dr Gunnel Hallden

Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al. ( 2023 ) . Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma . Pharmacological Reports vol. 75 , ( 3 ) 753 - 753 .

Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C et al. ( 2023 ) . A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma . Pharmacological Reports vol. 75 , ( 3 ) 570 - 584 .

Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM et al. ( 2021 ) . Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy . Acta Biomaterialia vol. 134 , 593 - 604 .

Stella Man YK, Foster J, Carapuça E, Davies JA, Parker AL, Sosabowski J, Halldén G ( 2019 ) . Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer . Scientific Reports vol. 9 , ( 1 )

Hallden G ( 2019 ) . Improved replication and selectivity of oncolytic Ad Delta Delta and Ad-3 Delta-A20T promotes targeting to distant lesions in preclinical pancreatic cancer models . HUMAN GENE THERAPY . Conference: IAM 2020 2021 vol. 30 , A7 - A8 .

Hallden G, Wang Y, Wong H-H, Lemoine NR ( 2019 ) . ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY . Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology , World Scientific Publishing

Nattress CB, Halldén G ( 2018 ) . Advances in oncolytic adenovirus therapy for pancreatic cancer . Cancer Letters vol. 434 , 56 - 69 .

Baker AT, Aguirre-Hernández C, Halldén G, Parker AL ( 2018 ) . Designer Oncolytic Adenovirus: Coming of Age . Cancers vol. 10 , ( 6 )

Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G ( 2018 ) . The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells . Molecular Cancer Therapeutics vol. 17 , ( 2 ) 575 - 587 .

Aguirre-Hernández C, Maya-Pineda H, Millán JS, Man YKS, Lu Y-J, Halldén G ( 2018 ) . Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy . Oncogenesis vol. 7 , ( 1 )

Aguirre-Hernandez C, Maya-Pineda H, Millan JS, Man YKS, Lu YJ, Hallden G ( 2017 ) . Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad Delta Delta through Bcl-2-dependent attenuation of autophagy . HUMAN GENE THERAPY . Conference: ESGCT workshop Croatia vol. 28 , A26 - A26 .

Man YKS, Davies JA, Coughlan L, Pantelidou C, Marshall JF, Parker AL, Hallden G ( 2017 ) . The novel oncolytic adenoviral mutant Ad5-3 Delta-A20T retargeted to alpha v beta 6-integrins efficiently eliminates pancreatic cancer cells . HUMAN GENE THERAPY . Conference: IAM Mexico vol. 28 , A27 - A27 .

Hallden G ( 2017 ) . Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses . vol. 28 , is. 8 , pp. A6 - A6 . Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,

Sweeney K, Halldén G ( 2016 ) . Oncolytic adenovirus-mediated therapy for prostate cancer . Oncolytic Virotherapy vol. 5 , ( 0 ) 45 - 57 .

Hernandez CA, Hallden G ( 2016 ) . The adenoviral AdDD mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells . HUMAN GENE THERAPY . Conference: ESGCT London vol. 27 , A5 - A6 .

Pantelidou C, Cherubini G, Lemoine NR, Halldén G ( 2016 ) . The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 . Oncotarget vol. 7 , ( 13 ) 15703 - 15724 .

Pantelidou C, Man YKS, Coughlan L, Marshall J, Kocher H, Hallden G ( 2016 ) . Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage . INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE vol. 38 , S58 - S58 .

Aguirre-Hernandez C, Millan JS, Hallden G ( 2016 ) . The adenoviral AdΔΔ mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells .

Pantelidou C, Hallden G ( 2015 ) . An oncolytic adenovirus (AdΔ19K) sensitizes pancreatic cancer cells to cytotoxic drugs by promoting DNA-damage and aberrant mitosis through inactivation of checkpoint mediators . HUMAN GENE THERAPY . vol. 26 , A19 - A20 .

Mercer EJ, Imrali A, Sharpe K, Hallden G, Lu Y-J ( 2014 ) . Abstract 713: Utilizing a potent and selective nonreplicating adenoviral mutant (Ad5-TV-CU), with gene expression controlled by androgen receptor-dependent activation domains in the TMPRSS2 gene, as a novel prodrug-converting enzyme therapy for prostate cancer . Cancer Research . vol. 74 , 713 - 713 .

Hallden G, Wang Y, Wong H-H, Lemoine NR ( 2014 ) . 18: ONCOLYTIC ADENOVIRUSES FOR CANCER GENE THERAPY . Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology , vol. 1 , World Scientific Publishing

Pantelidou C, Lemoine N, Hallden G ( 2014 ) . Adenoviruses deleted in the anti-apoptotic E1B19K-gene synergise with DNA-damaging drugs through attenuation of DNA-damage repair responses and checkpoint activation in pancreatic cancer cells . HUMAN GENE THERAPY . vol. 25 , A17 - A17 .

Man YKS, Coughlan L, Pantelidou C, Hallden G ( 2014 ) . Oncolysis is greatly enhanced by retargeting of replication-selective adenoviral mutants to avβ6-integrin expressing cancers and in combination with cytotoxic drugs . HUMAN GENE THERAPY . vol. 25 , A18 - A18 .

Passaro C, Abagnale A, Libertini S, Volpe M, Botta G, Cella L, Pacelli R, Halldèn G et al. ( 2013 ) . Ionizing radiation enhances dl922-947-mediated cell death of anaplastic thyroid carcinoma cells . Endocr Relat Cancer vol. 20 , ( 5 ) 633 - 647 .

Halldén G, Portella G ( 2012 ) . Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets . Expert Opin Ther Targets vol. 16 , ( 10 ) 945 - 958 .

Adam V, Ekblad M, Sweeney K, Müller H, Busch KH, Johnsen CT, Kang NR, Lemoine NR et al. ( 2012 ) . Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models . Hum Gene Ther vol. 23 , ( 9 ) 1003 - 1015 .

Botta G, Passaro C, Libertini S, Abagnale A, Barbato S, Maione AS, Hallden G, Beguinot F et al. ( 2012 ) . Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo . Hum Gene Ther vol. 23 , ( 6 ) 623 - 634 .

Sweeney KG, Cheong SC, Lemoine NR, Hallden G ( 2012 ) . Abstract 2712: A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells . Cancer Research vol. 72 , ( 8_Supplement ) 2712 - 2712 .

Maya-Pineda HR, Miranda-Rota E, Lemoine NR, Halldén G ( 2012 ) . Abstract 2713: Adenovirus E1A binding to p300 is essential for synergistic cell killing in combination with chemotherapeutic drugs in prostate cancer cells . Cancer Research vol. 72 , ( 8_Supplement ) 2713 - 2713 .

Halldén G ( 2012 ) . Adenoviral gene expression and replication in human tumor explant models . Methods Mol Biol vol. 797 , 65 - 78 .

Miranda E, Maya Pineda H, Öberg D, Cherubini G, Garate Z, Lemoine NR, Halldén G ( 2012 ) . Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region . PLoS One vol. 7 , ( 10 )

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Müller H, Lemoine NR, Halldén G ( 2011 ) . The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models . Gene Ther vol. 18 , ( 12 ) 1157 - 1165 .

Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Halldén G ( 2011 ) . An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine . Cancer Gene Ther vol. 18 , ( 10 ) 734 - 743 .

Sweeney K, Cheong SC, Lemoine N, Hallden G ( 2011 ) . A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells . HUMAN GENE THERAPY vol. 22 , ( 10 ) A122 - A122 .

Maya-Pineda H, Miranda E, Lemoine N, Hallden G ( 2011 ) . Adenovirus CIA binding to p300 is essential for synergistic cell killing in combination with chemotherapeutics in prostate cancer cells . HUMAN GENE THERAPY vol. 22 , ( 10 ) A104 - A104 .

Pantelidou C, Cherubini G, Lemoine NR, Hallden G ( 2011 ) . Adenovirus sensitizes pancreatic cancer cells to DNA-damaging chemotherapeutics through mitotic catastrophe induction and this is further enhanced by the deletion of the anti-apoptotic E1B19K gene . HUMAN GENE THERAPY vol. 22 , ( 10 ) A119 - A120 .

Ingemarsdotter CK, Baird SK, Connell CM, Öberg D, Halldén G, McNeish IA ( 2010 ) . Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer . Oncogene vol. 29 , ( 45 ) 6051 - 6063 .

Sweeney K, Cheong SC, Lemoine N, Hallden G ( 2010 ) . A non-replicating adenovirus expressing Hey1 is cytotoxic to prostate cancer cells . HUMAN GENE THERAPY . vol. 21 , 1398 - 1398 .

Ekblad M, Oberg D, Lemoine N, Hallden G ( 2010 ) . Development of an oncolytic adenovirus expressing the prodrug-converting enzyme CD/UPRT (Ad Delta Delta CU) . HUMAN GENE THERAPY . vol. 21 , 1473 - 1473 .

Radhakrishnan S, Miranda E, Ekblad M, Holford A, Pizarro MT, Lemoine NR, Halldén G ( 2010 ) . Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts . Hum Gene Ther vol. 21 , ( 10 ) 1311 - 1325 .

Cherubini G, Kalllin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N, Hallden G ( 2010 ) . Investigating a new potent and selective oncolytic adenovirus (Ad Delta Delta) in combination with chemotherapy . HUMAN GENE THERAPY . vol. 21 , 1473 - 1474 .

Ekblad M, Halldén G ( 2010 ) . Adenovirus-based therapy for prostate cancer . Curr Opin Mol Ther vol. 12 , ( 4 ) 421 - 431 .

Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine NR, Halldén G ( 2010 ) . Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers . Clin Cancer Res vol. 16 , ( 2 ) 541 - 553 .

Lee M, Choi S, Halldén G, Yo SJ, Schichnes D, Aponte GW ( 2009 ) . P2Y5 is a G(alpha)i, G(alpha)12/13 G protein-coupled receptor activated by lysophosphatidic acid that reduces intestinal cell adhesion . Am J Physiol Gastrointest Liver Physiol vol. 297 , ( 4 ) G641 - G654 .

Hallden G ( 2009 ) . Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics . J BUON vol. 14 , S61 - S67 .

Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA ( 2009 ) . Critical Role for p21 and p27 in Efficacy of Oncolytic Adenovirus dl922-947 in Ovarian Cancer . MOLECULAR THERAPY . vol. 17 , S100 - S100 .

Adam V, Oberg D, Lemoine N, Hallden G ( 2009 ) . Prostate Cancer Targeting by Replication-Selective Adenoviral Mutants: Combination Treatments with Phytochemical Drugs . MOLECULAR THERAPY . vol. 17 , S320 - S320 .

Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR, Halldén G ( 2009 ) . Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo . Clin Cancer Res vol. 15 , ( 5 ) 1730 - 1740 .

Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R, Hallden G, Portella G ( 2008 ) . Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947 . CLIN CANCER RES vol. 14 , ( 20 ) 6505 - 6514 .

Flak MB, Connell CM, Hill RM, Hallden G, Chelala C, McNeish IA ( 2008 ) . Host cell factors in ovarian cancer influencing efficacy of oncolytic adenovirus dl922-947 . HUMAN GENE THERAPY . vol. 19 , 1083 - 1083 .

Cheong SC, Oberg D, Nick L, Hallden G ( 2008 ) . Inhibition of late-stage prostate cancer using adenoviral mutants: Expression of an androgen receptor co-repressor and AR-siRNA . HUMAN GENE THERAPY . vol. 19 , 1082 - 1082 .

Adam V, Lemoine N, Hallden G ( 2008 ) . Prostate cancer targeting by replication-selective adenoviral mutants: combination treatments with phytochemical drugs . HUMAN GENE THERAPY . vol. 19 , 1165 - 1165 .

Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K, Fisher KD, Halldén G, Mautner V et al. ( 2008 ) . Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus . Hum Gene Ther vol. 19 , ( 9 ) 873 - 886 .

Seymour LW, Bazan-Peregrino M, Carlisle R, Hernandez-Alcoceba R, Iggo R, Homicsko K, Hallden G, Mautner V et al. ( 2008 ) . Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus . Hum Gene Ther

Adam VS, Lemoine N, Hallden G ( 2008 ) . Prostate cancer targeting by replication-selective adenoviral mutants: Combination treatments with phytochemical drugs . HUMAN GENE THERAPY . vol. 19 , 419 - 419 .

Cheong SC, Wang Y, Meng J-H, Hill R, Sweeney K, Kirn D, Lemoine NR, Halldén G ( 2008 ) . E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models . Cancer Gene Ther vol. 15 , ( 1 ) 40 - 50 .

Cheong SC, Lemoine N, Hallden G ( 2007 ) . Inhibition of androgen receptor signaling pathways in prostate cancer cells by adenoviral vectors expressing Hey1 . HUMAN GENE THERAPY . vol. 18 , 1004 - 1004 .

Gaballah K, Hills A, Curiel D, Hallden G, Harrison P, Partridge M ( 2007 ) . Lysis of dysplastic but not normal oral keratinocytes and tissue-engineered epithelia with conditionally replicating adenoviruses . CANCER RES vol. 67 , ( 15 ) 7284 - 7294 .

Radhakrishnan S, Hallden G, Chinegwundoh F, Lemoine N ( 2007 ) . Synergistic enhancement of prostate cancer cell death by combination therapy of adenovirus and chemotherapy . BJU INTERNATIONAL . vol. 99 , 28 - 28 .

Choi S, Lee M, Shiu AL, Yo SJ, Hallden G, Aponte GW ( 2007 ) . GPR93 activation by protein hydrolysate induces CCK transcription and secretion in STC-1 cells . AM J PHYSIOL-GASTR L vol. 292 , ( 5 ) G1366 - G1375 .

Gaballah K, Partridge M, Hills A, Curiel D, Hallden G, Harrison P ( 2007 ) . Lysis of dysplastic but not normal organotypical oral epithelium with conditionally replicating adenoviruses . ORAL ONCOLOGY . vol. 2 , 181 - 181 .

Radhakrishnan S, Hallden GK, Chinegwundoh F, Lemoine N ( 2007 ) . Synergistic enhancement of cell death by combination therapy with adenovirus and chemotherapy . JOURNAL OF UROLOGY . vol. 177 , 182 - 183 .

Bapat U, Wang Y, Alusi G, Chisholm E, Francis J, Hallden G, Lemoine N ( 2006 ) . Oncolytic virotherapy for nasopharyngeal cancer . Clinical Otolaryngology vol. 31 , ( 6 ) 582 - 583 .

Bhattacharyya M, Hallden G, Francis J, Lemoine NR ( 2006 ) . Synergistic interactions between adenovirus and chemotherapy in pancreatic cancer cell lines: Effects of chemotherapy on expression of coxsackie-adenovirus receptor (CAR) and infectability by adenovirus . CANCER RESEARCH . vol. 66 ,

Liu T-C, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D ( 2005 ) . Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus . Gene Ther vol. 12 , ( 17 ) 1333 - 1346 .

Wang Y, Xue S-A, Hallden G, Francis J, Yuan M, Griffin BE, Lemoine NR ( 2005 ) . Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors . Cancer Res vol. 65 , ( 4 ) 1523 - 1531 .

Lee M, Hadi M, Halldén G, Aponte GW ( 2005 ) . Peptide YY and neuropeptide Y induce villin expression, reduce adhesion, and enhance migration in small intestinal cells through the regulation of CD63, matrix metalloproteinase-3, and Cdc42 activity . J Biol Chem vol. 280 , ( 1 ) 125 - 136 .

Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D et al. ( 2005 ) . A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses . Clin Cancer Res vol. 11 , ( 1 ) 351 - 360 .

Hu JC, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes C ( 2004 ) . Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer in vitro . JOURNAL OF CLINICAL ONCOLOGY . vol. 22 , 57S - 57S .

Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, Patrick G ( 2004 ) . Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite . Int J Oncol vol. 25 , ( 1 ) 173 - 178 .

Liu T-C, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, Kirn D ( 2004 ) . An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency . Mol Ther vol. 9 , ( 6 ) 786 - 803 .

Hu J, Hallden G, Shorrock C, Simpson G, Coffin R, Kamalati T, Coombes R ( 2004 ) . Combination of a second generation genetically modified herpes simplex virus 1 (HSV 1) with paclitaxel in the treatment of breast cancer in vitro . MOLECULAR THERAPY . vol. 9 , S105 - S105 .

Hallden GK, Meng JH, Hill R, Wang YH, Francis J, Lemoine NN, Kirn DH ( 2004 ) . Combination therapy with adenovirus (Ad5) and cytotoxic drugs can act synergistically to induce cell death in carcinoma cell lines in culture . MOLECULAR THERAPY . vol. 9 , S113 - S113 .

Liu TC, Wang YH, Hallden G, Francis J, Brooks G, Lemoine N, Kirn D ( 2004 ) . Oncolytic adenovirus E1B-19kD deletion and E3B retention results in both enhanced potency and tumor necrosis factor-mediated selectivity . MOLECULAR THERAPY . vol. 9 , S109 - S109 .

Hill RJ, Hallden GK, Wang YH, Francis J, Simpson C, Kirn DH, Lemoine NR ( 2004 ) . The gene expression and function of adenoviral E3-genes in murine tumour cell lines . MOLECULAR THERAPY . vol. 9 , S374 - S375 .

Wang YH, Xue SA, Hallden G, Francis J, Griffin BE, Lemoine NR ( 2004 ) . VAI deleted adenovirus as an oncolytic agent targeting human EBV-associated tumours . MOLECULAR THERAPY . vol. 9 , S230 - S230 .

Halldén G, Thorne SH, Yang J, Kirn DH ( 2004 ) . Replication-selective oncolytic adenoviruses . Methods Mol Med vol. 90 , 71 - 90 .

Wang Y, Hallden G, Hill R, Anand A, Liu T-C, Francis J, Brooks G, Lemoine N et al. ( 2003 ) . E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models . Nat Biotechnol vol. 21 , ( 11 ) 1328 - 1335 .

Halldén G, Hill R, Wang Y, Anand A, Liu T-C, Lemoine NR, Francis J, Hawkins L et al. ( 2003 ) . Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy . Mol Ther vol. 8 , ( 3 ) 412 - 424 .

Liu TC, Wang YH, Hallden G, Anand A, Lemoine NR, Kirn DH ( 2003 ) . Adenoviral E1B-19kD deletion results in enhanced oncolytic effect and reduced toxicity in an immunocompetent murine tumor . MOLECULAR THERAPY . vol. 7 , S416 - S416 .

Hill RJ, Hallden GK, Lemoine NR, Kirn DH ( 2003 ) . In vitro screening of murine carcinoma cell lines for testing of replication-competent oncolytic adenoviruses . MOLECULAR THERAPY . vol. 7 , S362 - S362 .

Liu TC, Hallden G, Anand A, Wang YH, Lemoine N, Kirn D ( 2003 ) . Adenovirus E1B-19kD gene deletion enhances oncolytic virus efficacy and selectivity . CANCER GENE THERAPY . vol. 10 , S20 - S20 .

Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ ( 2002 ) . The emerging fields of suicide gene therapy and virotherapy . Trends Mol Med vol. 8 , ( 4 Suppl ) S68 - S73 .

Hallden G, Holehouse EL, Dong X, Aponte GW ( 1994 ) . Expression of intestinal fatty acid binding protein in intestinal epithelial cell lines, hBRIE 380 cells . American Journal of Physiology vol. 267 , ( 4 ) g730 - g743 .

Mulvihill SJ, Hallden G, Debas HT ( 1989 ) . Trophic effect of amniotic fluid on cultured fetal gastric mucosal cells . Journal of Surgical Research vol. 46 , ( 4 ) 327 - 329 .

Szecowka J, Hallden G, Goldfine ID, Williams JA ( 1989 ) . Purification of the pancreatic cholecystokinin receptor . Peptides vol. 24 , ( 3 ) 215 - 224 .